FrancophonIA/ELRC3.0 huggingface dataset:
English: Vomiting, Lip swelling, Abdominal pain, Abdominal pain upper, Paraesthesia oral
Danish: Mave-tarm-kanal en kvalme opkastning, hævede læber, abdominale smerter, smerter i den øverste del af abdomen, oral paræstesi
English: Confirm that patient identity matches the unique patient information located on the infusion bag(s) and metal cassette(s) prior to infusion.
Danish: Bekræft før infusion, at patientens identitet matcher de unikke patientoplysninger på infusionsposen(-erne) og metalkassetten/metalkassetterne.
English: Pyrexia, Influenza like illness, Chest discomfort, Chest pain, Injection site reaction, Catheter site haemorrhage, Catheter site bruise, Injection site bruising, Fatigue, Non-cardiac chest pain, Catheter site pain, Injection site pain, Puncture site pain, Pain
Danish: Almene symptomer og reaktioner på administrations-s tedet pyreksi, influenzalignende sygdom, ubehag i brystet, brystsmerter, reaktion på injektionsstedet, blødning/blå mærker/smerter ved kateterstedet, blå mærker på injektionsstedet, træthed, ikke-kardiale brystsmerter, smerter på kateterstedet, smerter på injektionsstedet, smerter på indstiksstedet, smerter
English: Keep the infusion bag(s) in the metal cassette(s).
Danish: Opbevar altid infusionsposen(-erne) i metalkassetten/-kassetterne.
English: Study HGB-204
Danish: Studie HGB-204
English: Among these 11 patients, the median (min, max) weighted average Hb during TI was 10.51 (9.3, 13.2) g/dL (Table 5).
Danish: af hæmoglobin (Hb) under TI på 10,51 (9,3; 13,2) g/dl (Tabel 5).
English: • bleeding or bruising
Danish: • blødning eller blå mærker
English: Petechiae, Ecchymosis, Pain of skin, Palpable purpura, Petechiae, Pruritus generalised, Purpura, Sweat gland disorder, Urticaria, Dry skin
Danish: Hud og subkutane væv alopeci, pruritus, hyperpigmenteret hud petekkier, ekkymoser, hudsmerter, palpabel purpura, generaliseret pruritus, purpura, sygdom i svedkirtlerne, urticaria, tør hud
English: (Second Infusion
Danish: (anden infusions-p ose)
English: Zynteglo is for intravenous use only (see section 6.6 for full details on the administration process).
Danish: Zynteglo er udelukkende til intravenøs anvendelse (se pkt.
English: Febrile neutropenia, Neutropenia, Thrombocytopenia, Leukopenia, Anaemia
Danish: Blod og lymfesystem febril neutropeni, neutropeni, trombocytopeni, leukopeni, anæmi,
English: (DD/MM/ YYYY)
Danish: {DD/MM/ ÅÅÅÅ}
English: A genetically modified autologous CD34+ cell enriched population that contains haematopoietic stem cells (HSC) transduced with lentiviral vector (LVV) encoding the βA-T87Q-globin gene.
Danish: En genetisk modificeret opformeret autolog CD34+- cellepopulation, som indeholder hæmatopoietiske stamceller (HSC), der er transduceret med en lentiviral vektor (LVV), der koder for βA-T87Q-globingenet.
English: • small tear in tissue that lines the anus
Danish: • små rifter i vævet omkring endetarmen
English: Zynteglo is a genetically modified autologous CD34+ cell enriched population that contains haematopoietic stem cells transduced with lentiviral vector encoding the βA-T87Q-globin gene.
Danish: Zynteglo er en genetisk modificeret autolog CD34+-beriget cellepopulation, som indeholder hæmatopoietiske stamceller (HSC), som er transduceret med en lentiviral vektor (LVV), der koder for βA-T87Q-globingenet.
English: Anal haemorrhage, Gastritis, Gastrointestinal inflammation, Abdominal distension, Abdominal pain upper, Anal fissure, Dyspepsia, Dysphagia, Oesophagitis, Haemorrhoids, Proctalgia.
Danish: Mave-tarm-kanalen stomatitis, opkastning, kvalme, diarré, gingival blødning, konstipation, mavesmerter, anal inflammation analblødning, gastritis, gastrointestinal inflammation, smerter i den øverste del af abdomen, analfissur, dyspepsi, dysfagi, oesophagitis, hæmorider, proktalgi, tørre læber
English: Skin and subcutaneous tissue disorders
Danish: Hud og subkutane væv udslæt, hyperhidrose
English: Blood magnesium decreased
Danish: Undersøgelser nedsat indhold af magnesium i blodet
English: Blood cell count determination and other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise.
Danish: Når der opstår kliniske symptomer, som antyder forekomst af blødning, skal bestemmelse af blodcelletallet og andre relevante analyser omgående overvejes.
English: HGB-205 HGB-204
Danish: HGB-205 HGB-204 HGB-207 HGB-212
English: Age median (min, max)
Danish: Alder median (min, max)
English: Respiratory, thoracic and mediastinal disorders
Danish: Luftveje, thorax og mediastinum dyspnø
English: Hypoxia, Dyspnoea, Pleural effusion, Rales, Upper-airway cough syndrome, Cough, Laryngeal pain, Hiccups
Danish: Luftveje, thorax og mediastinum epistaxis, inflammation i pharynx hypoksi, dyspnø, pleuraeffusion, rallelyd, upperairway cough syndrome, hoste, smerter i larynx, hikke
English: HGB-207 and HGB-212 are ongoing Phase 3 open-label, single-arm 24-month studies that are planned to include approximately 39 adults, adolescents, and children with TDT (N=23, HGB-207;
Danish: HGB-207 og HGB-212 er igangværende ikke-blindede, enkeltarmede fase 3-studier af 24 måneders varighed, der er planlagt til at omfatte cirka 39 voksne, unge og børn med TDT (N=23, HGB-207; N=16, HGB-212), hvoraf 29 har en non-β0/β0 genotype (N=23, HGB-207; N=6, HGB-212) og 10 har en β0/β0 genotype i HGB-212.
English: • increase of certain enzymes in the blood which may indicate a problem with your liver
Danish: • på grund af visse enzymer i blodet
English: Adverse reactions attributed to myeloablative conditioning
Danish: Tabel 2 Bivirkninger i forbindelse med myoblativ konditionering Systemorganklasse
English: Splenomegaly, Leukocytosis
Danish: Blod og lymfesystem trombocytopeni splenomegali, leukocytose,
English: Depending on the myeloablative conditioning agent administered, prophylaxis for seizures should be considered (see section 5.1 for a description of the prophylaxis regimen used in clinical studies.)
Danish: 5.1 for en beskrivelse af profylakseregimenet anvendt i kliniske studier).
English: Chemotherapy medicine
Danish: Kemoterapi
English: Cholecystitis, Cholelithiasis, Hepatomegaly, Jaundice, Transaminases increased, Gamma-glutamyltransferase increased
Danish: Lever og galdeveje venookklusiv leversygdom, forhøjet alaninaminotransferase (ALAT), forhøjet aspartataminotransferase (ASAT), forhøjet bilirubin i blodet cholecystitis, cholelithiasis, hepatomegali, gulsot, forhøjede transaminaser, forhøjet gamma-glutamyltransferase
English: Psychiatric disorders
Danish: Terapeutiske indikationer
English: Zynteglo, therefore the likelihood that an offspring would have general somatic expression of the βA-T87Q-globin gene is considered negligible.
Danish: Der er ingen mulighed for overførsel af βA-T87Q-globingenet via kønsceller efter behandling med Zynteglo, og derfor vil sandsynligheden for, at et afkom ville være i stand til at udtrykke βA-T87Q-globingenet være ubetydelig.
English: Vaginal haemorrhage
Danish: Vaskulære sygdomme hypotension
English: Hypotension, Haematoma
Danish: Vaskulære sygdomme hypotension, hæmatom
English: What Zynteglo is and what it is used for 2.
Danish: Virkning og anvendelse af Zynteglo 2.
English: Non-cardiac chest pain
Danish: Mave-tarm-kanalen mavesmerter
English: • inflammation of the gallbladder
Danish: • betændelse i fordøjelseskanalen
English: Haematuria
Danish: • udslæt
English: Hb ≥9 g/dL without any RBC transfusions for a continuous period of ≥12 months at any time during the study after infusion of Zynteglo.
Danish: Det primære endpoint var transfusionsuafhængighed (TI) efter 24 måneder, defineret som et vægtet gennemsnitligt Hb på ≥9 g/dl uden RBC-transfusioner i en sammenhængende periode på ≥12 måneder under hele studiet efter infusion af Zynteglo.
English: Agitation
Danish: Uforligeligheder
English: Expose the sterile port on the infusion bag by tearing off the protective wrap covering the port. Access the infusion bag and infuse per the administration site's standard procedures for administration of cell therapy products.
Danish: Tilgå infusionsposen med lægemidlet, og infundér det i henhold til centerets standardprocedurer for administration af celleterapiprodukter.
English: Final results: Q4
Danish: Endelige resultater:
English: Dizziness, Lethargy, Dysgeusia
Danish: Nervesystemet hovedpine svimmelhed, letargi, dysgeusi
English: Nederland bluebird bio (Netherlands) B.V. Tel: +31 (0) 303 100 450
Danish: Tlf.: +31 (0) 303 100 450
English: Hypoxia, Epistaxis
Danish: Luftveje, thorax og mediastinum hypoksi, epistaxis
English: The median (min, max) serum ferritin at baseline was 3778.7 (784, 22517) pmol/L and median (min, max) liver iron concentration was 6.75 (1.0, 41.0) mg/g (N=10, HGB-204; N=4, HGB-205; N=15, HGB-207; N=3, HGB-212).
Danish: for jernkoncentration i leveren var 6,75 (1,0; 41,0) mg/g (N=10, HGB-204; N=4, HGB-205; N=15, HGB-207; N=3, HGB-212).
English: Figure 1 Median total haemoglobin over time in non-β0/β0 TDT patients treated with Zynteglo who have achieved transfusion independence (Studies HGB-204,
Danish: Gennemsnitlig total hæmoglobin over tid i non-β0/β0 TDT-patienter, der blev behandlet med Zynteglo og har opnået transfusionsuafhængighed (studie HGB-204, HGB-205, HGB-207, LTF-303)
English: CD34+ cells)
Danish: (× 106 CD 34+ celler)
English: • flu like illness
Danish: • influenzalignende sygdom
English: Adverse reactions attributed to mobilisation/apheresis System Organ Class (SOC) Very Common (≥10%)
Danish: Tabel 1 Bivirkninger i forbindelse med mobilisering/aferese Systemorganklasse
English: How to store Zynteglo
Danish: Sådan skal du tage Zynteglo
English: Injury, poisoning and procedural complications
Danish: Traumer, forgiftninger og behandlingskomplikationer transfusionsreaktion, hudafskalning
English: Zynteglo is intended for autologous use (see section 4.4) and should only be administered once.
Danish: Zynteglo er beregnet til autolog anvendelse (se pkt.
English: Cardiac flutter
Danish: Hjerte atrieflimren
English: Metabolism and nutrition disorders
Danish: Metabolisme og ernæring nedsat appetit hypocalcæmi,
English: Mucosal inflammation, Face oedema, Hypothermia, Feeling cold, Pain, Xerosis
Danish: Almene symptomer og reaktioner på administrationsstedet pyreksi, træthed slimhindeinflammation, ansigtsødem, hypotermi, kuldefølelse, smerter, xerose
English: Bag ID
Danish: Pose-ID
English: Autologous CD34+ cells encoding βA-T87Q-globin gene This medicine is subject to additional monitoring.
Danish: Autologe CD34+ celler, der koder for βA-T87Q-globingenet.
English: Dyspnoea
Danish: Dosering
English: Conjunctival haemorrhage
Danish: Natriumindhold
English: • gum disease
Danish: • synkebesvær
English: Anxiety
Danish: Blødning
English: Table 3
Danish: Stadsplateau 7
English: Lot Number / COI ID
Danish: Lot-num mer/COIID
English: genotype, the MAH should submit interim data and the 5 years follow-up results of Study LTF-303.
Danish: For at bekræfte effekt og sikkerhed af Zynteglo hos patienter på 12 år eller mere med transfusionsafhængig β-thalassæmi (TDT), som ikke har en β0/β0- genotype, skal MAH'en indsende forløbige data og resultaterne efter 5 års opfølgning fra studie LTF-303.
English: Dispersion for infusion
Danish: Måneder efter infusion
English: Treatment is continued for as long as the patient benefits from it.
Danish: Behandlingen fortsættes, så længe patienten har gavn af den.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Caprelsa on 17 February 2012.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Caprelsa den 17. februar 2012.
English: The Committee noted the potential risk for QTc interval prolongation, and measures were introduced to minimise this risk.
Danish: Udvalget bemærkede den potentielle risiko for forlængelse af QTc-intervallet, og der blev iværksat tiltag for at minimere denne risiko.
English: The full EPAR for Caprelsa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Danish: Den fuldstændige EPAR for Caprelsa findes på agenturets websted: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This is a summary of the European public assessment report (EPAR) for Caprelsa.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Caprelsa.
English: The study involved 331 patients and the main measure of effectiveness was progression-free survival (how long the patients lived without their disease getting worse).
Danish: Undersøgelsen omfattede 331 patienter, og hovedeffektmålet var den progressionsfri overlevelsestid (hvor lang tid patienterne levede, uden at deres sygdom forværredes).
English: Caprelsa has been given ‘conditional approval'.
Danish: Caprelsa har fået en "betinget godkendelse".
English: Of the 16 children treated with Caprelsa, 7 (44%) had partial response on the ORR scale, which was comparable to the response rate in adults.
Danish: Af de 16 børn, der blev behandlet med Caprelsa, udviste 7 (44 %) delvis respons på ORR-skalaen, hvilket svarer til responsraten hos voksne.
English: The dose for children aged 5 years or older is calculated using the child's weight and height.
Danish: Hos børn i 5-årsalderen og opefter beregnes dosen ud fra barnets vægt og højde.
English: On average children taking Caprelsa lived for 46 months without their disease getting worse.
Danish: Børn, der fik Caprelsa, levede i gennemsnit i 46 måneder, uden at deres sygdom forværredes.
English: What measures are being taken to ensure the safe and effective use of Caprelsa?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Caprelsa?
English: Other information about Caprelsa
Danish: Andre oplysninger om Caprelsa
English: The main measure of effectiveness was ‘overall response rate' (ORR) which considers several features of the disease.
Danish: Hovedeffektmålet var den samlede responsrate (ORR), der tager flere af sygdommens egenskaber i betragtning.
English: On average, patients taking Caprelsa lived for 30.5 months without their disease getting worse, compared with 19.3 months for patients taking placebo.
Danish: Patienter, der fik Caprelsa, levede i gennemsnit i 30,5 måneder uden forværring af deres sygdom, sammenlignet med 19,3 måneder for de patienter, der fik placebo.
English: These enzymes are needed by certain receptors (such as VEGF, EGF and RET receptors) on the surface of cancer cells, where they activate several processes including cell division and the growth of new blood vessels.
Danish: Disse enzymer er nødvendige for visse receptorer (som f.eks. VEGF-, EGF- og RET-receptorer) på overfladen af kræftceller, hvor de aktiverer flere processer, herunder celledeling og dannelsen af nye blodkar.
English: Patients who cannot swallow tablets can mix the tablet in plain (non-sparkling) water.
Danish: Patienter, der ikke kan sluge tabletter, kan opløse tabletten i et glas vand (uden brus).
English: It must not be used in people with a problem called ‘congenital long QTc syndrome' or who have a QTc interval longer than 480 milliseconds.
Danish: Det må ikke gives til personer, der lider af "medfødt langt QTc-syndrom", eller som har et QTc-interval på over 480 millisekunder.
English: Patients must be given a patient alert card containing important safety information and they must be informed by their doctor about the risks of Caprelsa.
Danish: Patienterne skal have udleveret et patientinformationskort med vigtige sikkerhedsoplysninger og skal af deres læge oplyses om risiciene ved Caprelsa.
English: Caprelsa must not be used with other medicines that can prolong the QTc interval.
Danish: Caprelsa må ikke gives sammen med andre lægemidler, som kan forlænge QTc-intervallet.
English: By blocking the activity of VEGF receptors, the medicine reduces the blood supply to the cancer cells, slowing down the cancer's growth.
Danish: Ved at blokere VEGF-receptorernes aktivitet reducerer lægemidlet blodforsyningen til kræftcellerne, hvilket hæmmer cancerens vækst.
English: The most commonly reported side effects with Caprelsa are diarrhoea, rash, nausea (feeling sick), high blood pressure and headache.
Danish: De hyppigst indberettede bivirkninger ved Caprelsa er diarré, udslæt, kvalme, højt blodtryk og hovedpine.
English: Why is Caprelsa approved?
Danish: Hvorfor blev Caprelsa godkendt?
English: Therefore, the Committee recommended that Caprelsa be granted marketing authorisation.
Danish: Udvalget anbefalede derfor udstedelse af markedsføringstilladelse for Caprelsa.
English: This means that there is more evidence to come about the medicine, in particular on the size of the benefit in patients without the RET mutation.
Danish: Det betyder, at der afventes yderligere dokumentation om lægemidlet, navnlig vedrørende dets effektivitet hos patienter uden RET-mutation.
English: What is Caprelsa and what is it used for?
Danish: Hvad er Caprelsa, og hvad anvendes det til?
English: It is not intended to provide practical advice on how to use Caprelsa.
Danish: Det er ikke en praktisk vejledning i, hvordan Caprelsa bør anvendes.
English: The medicine is used when the disease is spreading quickly and causes symptoms, and when the cancer cannot be removed by surgery and has progressed or spread to other parts of the body.
Danish: Lægemidlet anvendes ved hurtigtspredende, symptomgivende sygdom, og når canceren ikke kan fjernes kirurgisk og har udviklet sig eller har bredt sig til andre dele af kroppen.
English: In a main study, Caprelsa was more effective than placebo (a dummy treatment) in adults with medullary thyroid cancer that could not be removed by surgery or had spread to other parts of the body.
Danish: I en hovedundersøgelse blev det påvist, at Caprelsa var mere effektivt end placebo (en virkningsløs behandling) hos voksne med medullær thyreoideacancer, der ikke kunne fjernes kirurgisk eller havde bredt sig til andre dele af kroppen.
English: In a second main study, Caprelsa was given to children aged between 9 and 17 years with hereditary medullary thyroid cancer.
Danish: I en anden hovedundersøgelse blev Caprelsa givet til børn mellem 9 og 17 år, der led af arvelig medullær thyreoideacancer.
English: The CHMP concluded that the benefits of Caprelsa outweigh its risks in patients whose disease is spreading quickly and is causing symptoms, since they are in urgent need of treatment.
Danish: CHMP konkluderede, at fordelene ved Caprelsa opvejer risiciene hos patienter, hvis sygdom er hurtigtspredende og symptomgivende, da de har akut brug for behandling.
English: The medicine can only be obtained with a prescription and treatment with Caprelsa should be started and supervised by a doctor who has experience of treating medullary thyroid cancer, of using cancer medicines and of assessing electrocardiograms (ECG, a test that measures the electrical activity of the heart).
Danish: Lægemidlet udleveres kun efter recept, og behandling med Caprelsa bør indledes og overvåges af en læge med erfaring i behandling af medullær thyreoideacancer, brug af kræftlægemidler og vurdering af elektrokardiogrammer (EKG, en test, som måler hjertes elektriske aktivitet).
English: Vandetanib also blocks the activity of RET receptors, which play a role in the growth of medullary thyroid cancer cells.
Danish: Vandetanib blokerer også aktiviteten af de RET-receptorer, som spiller en rolle i væksten af medullære thyreoideacancerceller.
English: Caprelsa can affect the electrical activity of the heart including a measurement called QTc interval.
Danish: Caprelsa kan påvirke den elektriske aktivitet i hjertet, herunder målingen for det såkaldte QTc-interval.
English: What are the risks associated with Caprelsa?
Danish: Hvilke risici er der forbundet med Caprelsa?
English: The company that markets Caprelsa will ensure that doctors who are expected to prescribe Caprelsa receive educational material containing important safety information about Caprelsa, including measures to manage the risk of QTc prolongation and other potential side effects, and a patient alert card and guidance for children or their carers.
Danish: Virksomheden, der fremstiller Caprelsa, skal sørge for, at læger, som forventes at ordinere Caprelsa, får materiale med vigtige sikkerhedsoplysninger om Caprelsa, herunder foranstaltninger til håndtering af risikoen for QTc-forlængelse og andre potentielle bivirkninger, et patientinformationskort og vejledning til børn eller deres omsorgsgivere.
English: What information is still awaited for Caprelsa?
Danish: Hvilke oplysninger afventes der stadig for Caprelsa?
English: Caprelsa contains the active substance vandetanib.
Danish: Caprelsa indeholder det aktive stof vandetanib.
English: The doctor may temporarily stop Caprelsa treatment and reduce the dose if the patient has abnormal ECG or severe side effects.
Danish: Lægen kan midlertidigt indstille behandlingen med Caprelsa og mindske dosen, hvis der hos patienten optræder unormale EKG-visninger eller alvorlige bivirkninger.
English: It must also not be used in women who are breast-feeding.
Danish: Det må heller ikke gives til patienter, der ammer.
English: The active substance in Caprelsa, vandetanib, is a ‘protein tyrosine kinase inhibitor'.
Danish: Det aktive stof i Caprelsa, vandetanib, er en "protein-tyrosinkinasehæmmer".
English: However, it was uncertain how well it works in patients without a mutation (change) in a gene called the ‘rearranged during transfection' (RET) gene or in patients whose RET mutation status is not known.
Danish: Det er dog uklart, hvor effektivt det er hos patienter, der ikke har en mutation i det såkaldte RET-gen (RET = rearranged during transfection), eller hvis RET-mutationsstatus ikke er kendt.
English: The CHMP concluded that Caprelsa was shown to be effective in the treatment of medullary thyroid cancer in patients aged 5 years and older.
Danish: CHMP konkluderede, at Caprelsa har vist sig at være effektivt til behandling af medullær thyreoideacancer hos patienter fra 5-årsalderen og opefter.
English: The company that markets Caprelsa will carry out a study in patients with medullary thyroid cancer to compare the effects of Caprelsa in patients with and without the RET mutation.
Danish: Virksomheden, der fremstiller Caprelsa, vil gennemføre en undersøgelse hos patienter med medullær thyreoideacancer for at sammenligne virkningen af Caprelsa hos patienter med og uden RET-mutation.
English: It is recommended that the doctor checks for RET mutation at the start of Caprelsa treatment.
Danish: Det anbefales, at lægen kontrollerer patientens RETmutationsstatus, inden behandlingen med Caprelsa indledes.
English: For more information about treatment with Caprelsa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Caprelsa, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: Caprelsa may work less well in patients without a mutation (change) in a gene called the ‘rearranged during transfection' (RET) gene.
Danish: Caprelsa er muligvis mindre virksomt hos patienter, der ikke har en mutation i det såkaldte RET-gen (RET = rearranged during transfection).
English: Caprelsa is available as tablets (100 mg and 300 mg) and the recommended dose for adults is 300 mg once a day, taken at around the same time each day.
Danish: Den anbefalede dosis er 300 mg én gang dagligt på omtrent samme tidspunkt.
English: For the full list of all side effects reported with Caprelsa, see the package leaflet.
Danish: Den fuldstændige liste over indberettede bivirkninger ved Caprelsa fremgår af indlægssedlen.
English: Caprelsa is a cancer medicine that is used in adults and children above 5 years of age to treat medullary thyroid cancer, a cancer that starts off in the cells in the thyroid gland that produce the hormone calcitonin.
Danish: Caprelsa er et kræftlægemiddel til børn over 5 år og voksne, der lider af medullær thyreoideacancer, en kræftform, der opstår i de celler i skjoldbruskkirtlen, der producerer hormonet calcitonin.
English: This means that it blocks the activity of enzymes known as tyrosine kinases.
Danish: Det vil sige, at stoffet blokerer enzymer af tyrosinkinasetypen.